Genflow Biosciences Secures EU Patent, Strengthens IP Protection for Longevity Therapies

Genflow Biosciences has secured a major European patent for its sirtuin 6 variant, a core element of its longevity therapeutic platform. CEO Dr Eric Leire describes the development as a "major step" that creates a strong defensive barrier against competition. The patent enhances the company's attractiveness to potential pharmaceutical partners and is crucial for small biotech firms like Genflow. Leire expects the patent to accelerate early-stage deals around other therapeutic targets and points to the upcoming efficacy readout from the company's Dutch study as the next major milestone.